Answer
Worsening of pre-existing heart failure was reported in pooled placebo-controlled studies of non-dialysis patients in 13.6% receiving sodium zirconium cyclosilicate (Lokelma) versus 5.7% receiving placebo, with most cases resolving with appropriate clinical management without withdrawing Lokelma.
Sources for this answer
- Lokelma 5 g powder for oral suspensionAstraZeneca UK Limited · emc · SmPC §4.8 Undesirable effects · Version 12Document updated
Sources checked